Evaxion Biotech A/S
EVAX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $3,344 | $73 | $0 | $0 |
| % Growth | 4,480.8% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $3,344 | $73 | $0 | $0 |
| % Margin | 100% | 100% | – | – |
| R&D Expenses | $10,457 | $11,916 | $17,056 | $19,583 |
| G&A Expenses | $7,317 | $10,079 | $8,064 | $6,180 |
| SG&A Expenses | $7,317 | $10,079 | $8,064 | $6,180 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $302 | $275 | $144 | $71 |
| Operating Expenses | $18,076 | $22,270 | $25,264 | $25,834 |
| Operating Income | -$14,732 | -$22,197 | -$25,264 | -$25,834 |
| % Margin | -440.6% | -30,406.8% | – | – |
| Other Income/Exp. Net | $3,377 | -$718 | $1,323 | $1,124 |
| Pre-Tax Income | -$11,355 | -$22,915 | -$23,941 | -$24,710 |
| Tax Expense | -$788 | -$790 | -$772 | -$178 |
| Net Income | -$10,567 | -$22,125 | -$23,169 | -$24,532 |
| % Margin | -316% | -30,308.2% | – | – |
| EPS | -9.8 | -32.4 | -39.2 | -50.4 |
| % Growth | 69.8% | 17.3% | 22.2% | – |
| EPS Diluted | -9.8 | -32.4 | -39.2 | -50.4 |
| Weighted Avg Shares Out | 1,073 | 683 | 591 | 487 |
| Weighted Avg Shares Out Dil | 1,073 | 683 | 591 | 487 |
| Supplemental Information | – | – | – | – |
| Interest Income | $254 | $154 | $2,831 | $2,039 |
| Interest Expense | $962 | $897 | $1,508 | $915 |
| Depreciation & Amortization | $607 | $615 | $571 | $344 |
| EBITDA | -$9,786 | -$21,403 | -$22,572 | -$24,207 |
| % Margin | -292.6% | -29,319.2% | – | – |